Feature: Xenotransplantation offers hope to diabetes sufferers
16 August, 2010 by Fiona WylieBack when Living Cell Technologies's (LCT) current Medical Director and Founder, Professor Bob Elliott, was working in his Auckland clinic, he decided that the treatments available for patients with Type I diabetes simply weren't good enough.
New study to turn cancer research on its head
02 August, 2010 by David BinningResearchers at the Walter and Eliza Hall Institute (WEHI) have shown that programmed cell death or apoptosis, a process which has typically been assumed to prevent or slow the development of cancer, may in some instances contribute to its spreading.
Link between HIV drugs and heart attack
30 July, 2010 by David BinningA study by Sydney researchers showing that the protease inhibitor type of HIV drugs carry a greater risk of heart attack than the new integrase inhibitor family of drugs is expected to have major implications for the future direction of treatment.
WAIMR to fund two new melanoma projects
30 July, 2010 by Staff WritersThe Western Australian Institute for Medical Research (WAIMR) has awarded grants of $75,000 each to two of its scientists hoping to identify new treatments for melanoma as well as boost the effectiveness of chemotherapy drugs against the disease.
Study shows antibiotics could help fight malaria
29 July, 2010 by David BinningIn a major breakthrough for malaria treatment European researchers have shown that mice infected with the disease administered antibiotics developed immunity against re-infection.
First glimpse into Cancer Genome Project
23 July, 2010 by David BinningInitial data from the world’s largest ever study correlating the genes of cancer sufferers with their responses to medications have been released indicating the potential for promising future treatments.
New treatment for Type 2 diabetes
23 July, 2010 by Staff WritersScientists from Sydney’s Garvan Institute have demonstrated that the drug candidate Lisofylline may be useful in the treatment of Type 2 diabetes.
Feature: RNAi delivers double whammy to cancer
22 July, 2010 by Graeme O'NeillRNA interference (RNAi) was little more than an enigmatic laboratory phenomenon just 15 years ago, but has since been fashioned into a Swiss Army knife, bristling with new blades and widgets for biological and medical research.
Ecstasy study gives hope to PTSD sufferers
21 July, 2010 by David BinningUS researchers have published the results of the first ever clinical trial examining the effectiveness of MDMA in treating sufferers of post traumatic stress disorder (PTSD).
Andrew ‘Twiggy’ Forest moves to take control of Coridon
19 July, 2010 by Staff WritersIron ore magnate Andrew ‘Twiggy’ Forest is poised to make his foray into the Australian biotech industry with his medical devices company Allied Medical announcing it was undertaking a rights issue to buy a controlling interest in Brisbane vaccine specialists Coridon.
UQ and Alere team to develop dengue fever test
16 July, 2010 by Staff WritersThe University of Queensland has teamed up with local dengue fever specialists Alere Australia to develop a low-cost diagnostic test for the potentially fatal disease.
Feature: A world without malaria
13 July, 2010 by Graeme O'NeillMalaria is not only devastating to the individuals who suffer from it, but it also prevents many of the poorest countries around the world from emerging from poverty. A 2001 report by the Center for International Development found that countries with widespread malaria infection had income levels only one third that of similar countries without malaria - and that's adjusting for all other variables. So malaria is not just a health issue, it's a massive socio-political problem, the solving of which could benefit untold millions.
U.S scientists identify chemicals that grow brain cells
09 July, 2010 by Staff WritersResearchers at the Emory University School of Medicine in Atlanta have identified chemicals that help to grow neurons in the brains of mice, potentially leading to new treatments for mental illness and cognitive disabilities.
Sales of generic HIV drugs to surge as patents expire
08 July, 2010 by David BinningSales of generic HIV drugs will double to more than $US1.2 billion by 2019 making up 10 percent of the entire retroviral market, according to industry analysts Datamonitor.
Protein from lizard embryos could advance cancer research
29 June, 2010 by Staff WritersA protein key to the development of placenta in pregnant lizards may open the door to a promising new branch of cancer research.
